Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering &
Processing Services
- Framework agreement with Actelion Pharmaceuticals Ltd. signed
- Actelion receives system solutions in the areas of gene
optimization, gene synthesis and plasmid preparation exclusively from
GENEART from now on
- The service portfolio of GENEART accelerates product development in
biotechnology when compared to conventional methods of molecular
biology
- DIN EN ISO 9001:2000 certification guarantees high quality
standards for the development of pharmaceutical agents
Regensburg, July 7, 2009 - GENEART AG, global leader in Gene
Synthesis and specialist in the field of Synthetic Biology, announces
the signing of a framework agreement with the Swiss company Actelion
Pharmaceuticals Ltd. Within the scope of this agreement, Actelion
will receive system solutions for DNA engineering & processing (gene
optimization, gene synthesis and plasmid preparation) exclusively
from GENEART from now on. Further contract terms were not disclosed.
The contract does not restrict GENEART in supplying service solutions
for other customers. The company, listed in the Swiss blue-chip index
SMI®, is active in research, development and commercialization of
innovative biopharmaceutical therapies. The drugs developed and
marketed by Actelion include Tracleer® for instance - an endothelin
receptor antagonist for patients with pulmonary arterial
hypertension.
"We are delighted that we have been able to convince another
well-known company, Actelion, of the advantages of our technology for
the development of biopharmaceutical therapeutics. Gene optimization
and gene synthesis offer many advantages over conventional methods in
molecular biology. For instance, genes can be tailored to the
respective customer project by our GeneOptimizer® software without
any restrictions and subsequently produced within a few days. This
not only shortens development times for biopharmaceuticals, but also
increases the yield and thus reduces production and project costs.
The fully DIN EN ISO 9001:2000 certified processes of GENEART and the
world-wide highest production capacities additionally ensure reliable
and quick processing of customer projects with observance of the
required quality standards for the development of pharmaceutical
agents", Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.
For further inquiries, please contact:
Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com
Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de
Legal Information:
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001:2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. GENEART AG in
Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto
(Canada) and GENEART Inc. in San Francisco (USA) employ more than 190
people. GENEART is listed on the German Stock Exchange.
About Actelion Pharmaceuticals Ltd.:
Actelion Pharmaceuticals Ltd. is a biopharmaceutical company with its
corporate headquarters in Allschwil/Basel, Switzerland. Actelion's
first drug Tracleer®, an orally available dual endothelin receptor
antagonist, has been approved as a therapy for pulmonary arterial
hypertension. Actelion markets Tracleer® through its own subsidiaries
in key markets worldwide, including the United States (based in South
San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in
innovative science related to the endothelium - the single layer of
cells separating every blood vessel from the blood stream. Actelion's
over 2,000 employees focus on the discovery, development and
marketing of innovative drugs for significant unmet medical needs.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol:
ATLN) as part of the Swiss blue-chip index SMI® (Swiss Market Index).
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.